Please use this identifier to cite or link to this item:
https://scholarhub.balamand.edu.lb/handle/uob/5904
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shaib, Walid L | en_US |
dc.contributor.author | Nammour, Jean Paul A | en_US |
dc.contributor.author | Gill, Harpaul | en_US |
dc.contributor.author | Mody, Mayur | en_US |
dc.contributor.author | Saba, Nabil F | en_US |
dc.date.accessioned | 2022-07-26T06:41:49Z | - |
dc.date.available | 2022-07-26T06:41:49Z | - |
dc.date.issued | 2016-01-14 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarhub.balamand.edu.lb/handle/uob/5904 | - |
dc.description.abstract | The prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. Comprehensive genomic sequencing has defined some molecular alterations with potential targets, but the majority of patients still do not benefit from druggable targets. Breakthroughs in immune checkpoint blockade have provided new therapeutic options in many cancers. Programmed death ligand 1 (PDL1) overexpression, a possible biomarker predicting response to immune checkpoint inhibitors, approaches forty percent in esophageal and gastric cancers. Translational and molecular studies have shown that esophageal cancers are possible candidate malignancies for immune checkpoint inhibition. In this review, we plan to highlight the mechanisms, preclinical, and early clinical data that provide insight on the role of immune therapeutics in esophageal cancers. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | National Library of Medicine | en_US |
dc.subject | Esophageal cancer | en_US |
dc.subject | Immune therapy | en_US |
dc.subject | Progress | en_US |
dc.title | The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma | en_US |
dc.type | Journal Article | en_US |
dc.identifier.doi | 10.3390/jcm5110100 | - |
dc.identifier.pmid | 27854242 | - |
dc.identifier.scopus | 2-s2.0-85065795211 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85065795211 | - |
dc.contributor.affiliation | Faculty of Medicine | en_US |
dc.description.volume | 5 | en_US |
dc.description.issue | 11 | en_US |
dc.date.catalogued | 2022-07-26 | - |
dc.description.status | Published | en_US |
dc.identifier.openURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126797/ | en_US |
dc.relation.ispartoftext | Journal of Clinical Medicine | en_US |
dc.description.campus | SGH campus | en_US |
Appears in Collections: | Faculty of Medicine |
SCOPUSTM
Citations
7
checked on Nov 16, 2024
Record view(s)
40
checked on Nov 22, 2024
Google ScholarTM
Check
Altmetric
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.